Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 20Thoracic 4Genitourinary 3Gastrointestinal 3Breast 3Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Breast Neoplasms 543Triple Negative Breast Neoplasms 97Ovarian Neoplasms 58Colorectal Neoplasms 50Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 44Neoplasms 38Lung Neoplasms 33Melanoma 29Endometrial Neoplasms 29Neoplasm Metastasis 28Stomach Neoplasms 26Pancreatic Neoplasms 26Uterine Cervical Neoplasms 25Squamous Cell Carcinoma of Head and Neck 22Colonic Neoplasms 20Head and Neck Neoplasms 18Carcinoma, Renal Cell 18Esophageal Neoplasms 16Sarcoma 14Advanced Breast Cancer 14Small Cell Lung Carcinoma 13Urinary Bladder Neoplasms 12Liver Neoplasms 11Carcinoma, Transitional Cell 11Kidney Neoplasms 10Carcinoma, Intraductal, Noninfiltrating 10Brain Neoplasms 10Lymphedema 9Anatomic Stage I Breast Cancer AJCC v8 9

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Breast × 30 days × Clear all
NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Myeloid Therapeutics

Phase 1 Recruiting
60 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04902872 2026-05-12

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Cybrexa Therapeutics

Phase 1/2 Completed
69 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Appendiceal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04152499 2026-05-11

MK-2870-001

Klus Pharma Inc.

Phase 1/2 Active not recruiting
1,410 enrolled
BreastGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡